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Abstract: Homepregnancy tests (HPTs) available in Europe
include accuracy and other performance claims listed on
their packaging. Due to the lack of guidance on the stand-
ardisation of such products, it is often difficult to replicate
these claims when tested on a clinical sample, whether in a
laboratory setting or by lay users. The In Vitro Diagnostic
Regulation is a set of requirements that mandate compre-
hensive validation data on human pregnancy tests and
other in vitro devices. It is due to replace the current Euro-
pean Directive (98/79/EC) and fully implemented in Europe
by 2022. In June 2019, a panel of seven experts convened to
discuss the validation studies required to provide the in-
formation needed to meet the new regulation for HPTs in
Europe and proposed 15 recommendations for best practice.
Defining best practice at all stages of validation of these
important testsmayensure that testsmarketed inEuropeare
fit for purpose, enabling lay users to be confident of the high
quality of the HPT results they obtain. The panelists believe
that the recommendations proposed here for the validation
of HPTs may constructively contribute to improved stand-
ardisation of validation procedures in Europe.
Keywords: European Directive; home pregnancy tests;
human chorionic gonadotrophin; in vitro diagnostic
regulation; validation testing.
Introduction
Home pregnancy tests (HPTs) became widely available in
1976, enabling women to determine their pregnancy sta-
tus in the privacy and comfort of their own homes [1–3].
Significant technical innovations have resulted in the
development of the tests used today. These have simple,
one-step direct sampling formats with either colouri-
metric or digital outputs that facilitate interpretation as
positive, negative or equivocal [2, 3]. The basis of all
pregnancy tests is detection of the hormone human cho-
rionic gonadotrophin (hCG) [2]. hCG is a glycoprotein that
has a structure consisting of two non-covalently linked
dissimilar α- (91 amino acids) and β- (145 amino acids)
subunits [1, 2]. Following implantation, the placenta be-
gins to develop, gradually producing increasing amounts
of hCG until weeks 10–12 of pregnancy, after which the
hCG concentration decreases moderately and stabilises
until late pregnancy, with a further decrease during the
last month [2]. hCG is not present in measurable concen-
trations in non-pregnant, pre-menopausal women except
in relatively rare malignancies [4]. Its measurement,
therefore, has enabled development of both laboratory
tests and HPTs for detection of pregnancy [2].
At least 65 million HPTs are sold in Europe each year
[5]. These are available as strips, cassettes and mid-stream
dipsticks. Mid-stream tests either have results displayed as
a line or cross for visual interpretation by the user (visual
tests, also known as line tests) or the results are displayed
digitally to the user on an LCD screen (digital tests) [5]. The
characteristics of typical devices are shown in Table 1.
Many HPTs are sold over the counter for home use, others
are intended for professional use only [6].
HPTs are designed for single use for qualitative detec-
tion of hCG in a urine specimen collected at any time of the
day, with a positive result indicating possible pregnancy [7].
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However, detection limits may vary considerably, with one
study reporting detection limits ranging from 6.3 to 50 IU/L
[8]. There is currently nouniversal standardisation guidance
for medical devices such as HPTs; thus, their analytical and
clinical performance inevitably vary considerably [9]. The
US Food and Drug Administration (FDA) has published
summaries of HPTs cleared for sale in the USA, thereby
providing some indication of how validation is being con-
ducted. Details of the tests performed and the type of hCG
samples used are included in these summaries [10, 11].
Table 2 illustrates the variability in testing of analytical
precision for fourHPTs recently cleared by the FDA,with the
number of tests performed during evaluation ranging from
540 to 6,000 [10]. It is highly desirable that validation of
HPTs includes assessment of their clinical accuracy when
used by non-laboratory personnel, but how rigorously
this is assessed also varies markedly as presented in
Table 2 [11].
Currently, tests available in Europe include accuracy
and other performance claims on their packaging. How-
ever, as illustrated above, the lack of standardised criteria
against which performance can be assessed makes it
difficult to compare results for analytical accuracy [2].
This also applies to claims for clinical accuracy, i.e. the
correct determination of “pregnant” (positive) and “non-
pregnant” (negative) results for specimens for which the
true clinical status is known. Many HPTs claim to be more
than 99% clinically accurate when used from the day of
the missed menstrual period, but it is not always clear
how this was determined – a problem highlighted in the
USA almost two decades ago [8]. Different approaches
can yield differing results depending on the types of
specimens used for testing, sample size and other factors,
as well as the selection of lay users contributing to
validation studies.
A recent study reported that only three of seven HPTs
available on the European market met accuracy and
reliability claims of >99% of the products’ claimed
analytical sensitivity (i.e. the stated concentration of hCG
at which the product is expected to return pregnant re-
sults), while the other four tests had analytical accuracies
of <99% (81.6–95.9%) [12]. In this context, it is important
to note that if such assessments are performed by trained
laboratory technicians under ideal conditions [2, 13] they
may not reflect real-life usage. As the main aim of
analytical validation is to demonstrate that the procedure
is suitable for its intended purpose [14], for HPTs it is
essential that there is clear evidence that the test can be
successfully performed by lay users.
Manufacturers who market HPTs in the USA are now
required by the FDA to provide evidence of product per-
formance that includes data for testing analytical and
Table : Broad characteristics of HPTs commonly available in Europe.a
Device format Strip Cassette Mid-stream visual Mid-stream digital
Mode of specimen
collection
Sample collected in a container
(usually not supplied with the
test).
Sample collected in a
container (usually not sup-
plied with the test).
A sample pipette is usually
provided with the kit for
sample application.
Sample by holding directly
into the urine stream.
Alternatively, most
mid-stream tests also
provide an option for dip-
ping the sampling wick into
a collected sample.
Sample by holding directly into the
urine stream.
Alternatively, most mid-stream
tests also provide an option for




Strip dipped into specimen up to
the “dip line” for the sampling
time (usually – s).
Urine applied by pipetting
a set number of drops to
sample well (usually –
drops).
Held in the urine stream for
a prescribed time period
(usually – s). Dipping
time may differ from
in-stream sampling time.
Held in the urine stream for a pre-
scribed time period (usually
– s). Dipping time may differ
from in-stream sampling time.
Signal detection /
read-out
Colourimetric Colourimetric Colourimetric Digital
Range of time to
read-out
– min
Do not read generally after
 min.
– min
Do not read generally after
 min.
– min
Do not read generally after
 min.
– min
Digital results remain valid until
display screen goes blank
(days–months).
aAll require use of urine as the specimen. Exact sampling times or requirements should be clearly defined in each products’ instructions for use.
The sampling times, amount of urine to be applied, and reading timesprovided in the table above are typical, but some testsmay vary from these
instructions. HPT, home pregnancy test.
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clinical sensitivity, equivalency of results when using
different samplingmethods (e.g. sampling directly in urine
stream and dip, or dipping into a collected sample) and
early pregnancy detection rate before the menstrual
period is missed [2]. The current guidance document from
the FDA (Guidance for over-the-counter [OTC] human
chorionic gonadotrophin [hCG] 510[k]s) is out of date and
awaiting revision [15], but recent information is available
from the FDA detailing current FDA testing requirements,
and Clinical Laboratory Standards Institute (CLSI)
guidelines can also be used to guide testing. However,
manufacturers are not required to meet these FDA
requirements for the European market and in the absence
of other recommendations, there is a notable lack of
transparency and detailed information regarding HPTs
available in Europe.
This lack of guidance will in part be addressed by
the new In Vitro Diagnostic Regulation (IVDR), a set of
requirements due to replace the current European
Directive (98/79/EC). Transition to the IVDR commenced
in May 2017, with the intention of full enforcement in
Europe by 2022 [16, 17]. The requirements include the ne-
cessity for comprehensive validation data (including data
on customer usability) on HPTs and other in vitro devices
[17, 18].
An expert panel (with the following members: Dr Ste-
phen Butler [Clinical Research Scientist]; Dr Fiona Gould
[Industry, Regulatory Expert]; Professor David Grenache
[Director of Clinical Reference Laboratory]; Dr Sarah Johnson
[Industry, Diagnostics Expert]; Dr Sam Rowlands [Specialist
in Sexual and Reproductive Health]; Professor Ulf-Håkan
Stenman [Emeritus Professor of Clinical Chemistry] and Dr
Catharine Sturgeon [Director of UKNational External Quality
Assessment Service for Pregnancy Testing]) convened in
London (UK) in June 2019 to consider these issues and the
validation studies required for HPTs available in Europe as
these new regulations come into force. While HPTs were
specifically considered at that meeting, the conclusions are
equally valid for pregnancy tests intended for use by health
professionals in hospitals and other healthcare settings. As
there are international standards relating to the validation of
shelf life and stability of HPTs, these were not considered by
the panel. Key literature references used to guide the dis-
cussion are listed in Supplementary Table 1.
The panel’s recommendations for best practice are
described below and key points are highlighted in Table 3.
The panel encourage manufacturers to apply these recom-
mendations during implementation of the new IVDRand for
notified bodies to use this guidance when examining the
data underpinning HPT performance.
Table : Validation studies conducted to assess the precision of four FDA-cleared HPTs with claimed analytical sensitivities of  U/L.a
Device Mid-stream test
K












Number of hCG specimens in the
testing panel
   








hCG concentrations added to
“non-pregnant” urine, IU/L
, , , , ,  , ., , , ., , , ,
, , 
, , , ., , ,
, 
, , , ., , , , 
Number of replicates per
condition
   
Number of consecutive days on
which tests performed
   
Number of lots tested    
Number of operators  (different operator on
each different day)
Three operators at three sites
(total of nine operators)
 Not stated, three sites used
(a different test format
at each site)
Total number of tests done  Three formats of tests
examined
, per format
Two formats of tests
examined
, per format
Three formats of tests
examined
, per format
aSource of the hCG used for these studies not specified. The K number is the FDA device registration number that can be used as a unique
identifier for the product. FDA, US Food andDrug Administration; hCG, human chorionic gonadotrophin; HPT, home pregnancy test; WHO,World
Health Organisation.
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Requirements for validation of HPTs
in Europe
Achieving consistency for the validation of these important
tests requires agreement regarding the pre-analytical,
analytical, clinical and user assessments that should be
undertaken, as well as how this information should be
presented to enable ready comparison of data fromdifferent
sources. Panel recommendations are presented below.
Considerations relating to nomenclature
Description of device formats
HPTs are available in a number of formats (Table 1).
Reaching broad agreement about how these tests should
be described and adoption of consistent nomenclature for
the different types of tests would assist individual lay
users to decide which type of test they would find most
convenient to use.
Recommendation: Agreement on the broad de-
scriptions of different types of device formats is a priority.
Description of hCG isoforms recognised
Recognition of isoforms of hCG
Numerous isoforms of hCG exist in urine, and not all assays
detect the various forms to the same extent. Intact hCG
(in which the α- and β-subunits remain associated) is the
predominant urinary form in early pregnancy [19]. In early
pregnancy the free β-subunit of hCG (hCGβ) is present at a
concentration below 10% of that of intact hCG and is not
detected inmany HPTs [20–24]. The β core fragment of hCG
(hCGβcf), a metabolically degraded fragment of hCGβ, is
undetectable in early-pregnancy urine, but becomes the
predominant form by 10 weeks of gestation [21, 25]. hCG
and the nicked form are less stable than hCGβ [26]. In
quantitative assays, these variations can lead to different
“total” hCG results for clinical specimens, depending on
the concentrations of the hCG isoforms present [26]. Inter-
national standards available for most forms of hCG enable
characterisation of quantitative assays in terms of their
detection of the different forms [26–31]. The panel consid-
eredwhetherHPTs should undergo similar characterisation.
HPTs provide qualitative results only – they indicate
whether the hCG concentration is above or below a certain
claimed detection limit. The panel agreed that information
relating to recognition of different hCG isoforms by HPTs is
not relevant for lay users, as actual clinical performance in
relation to pregnancy status is the keymetric. However, it is
important that manufacturers assess which isoforms of
hCG are recognised by each HPT during early characteri-
sation of the method (Section “Units of measurement”).
This can be conveniently achieved using existing Interna-
tional Reference Reagents for these isoforms and express-
ing comparative results in substance concentrations
(mol/L) assigned to these Reference Reagents [26].
Recommendation: Manufacturers should include
data regarding the relative recognition of hCG isoforms as
expressed in molar units (mol/L) in technical data sheets.
Units of measurement
Achieving agreement regarding the units in which hCG
concentrations are expressed for HPTs would be desirable.
In an FDA guidance document for OTC hCG tests, the units
used throughout are mIU/mL [15]; these units are estab-
lished by theWorld Health Organisation Expert Committee
on Biological Standardization. Originally based on hCG
bioactivity measurements, these somewhat arbitrary units
were assigned by bioassay to each successive International
Standard for hCG to maintain continuity of clinical hCG
results (and pharmacological hCG preparations). Adoption
of molar units (substance concentrations) enables direct
comparison of recognition of different forms of hCG as
described above and facilitates analytical standardisation
of both qualitative and quantitative hCG methods. The
International Federation of Clinical Chemistry and Labo-
ratory Medicine recommends the use of substance con-
centrations (mol/L) wherever possible; however, it was
accepted by the panel that as clinicians and lay users are
familiar with hCG results expressed in mIU/mL, IU/L or
U/L, changing to molar or mass units would cause
considerable confusion. It would be desirable to express
results in terms of U/L, the units for hCG used in most
clinical laboratories. However, when comparing concen-
trations of hCGβ and hCGβcf with hCG, molar units must be
used. Earlier established International Units (IUs) for hCGβ
are not at all comparablewith IUs of hCG and the standards
for hCGβ and hCGβcf have not been assigned a value in IU.
Recommendation: hCG results should be expressed
using the same units, ideally U/L.
Analytical requirements for validation of
HPTs
Validation studies for HPTs differ from those for many
diagnostic tests performed in clinical laboratories as they
include studies conducted both by the diagnostic
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companies manufacturing the HPT and by lay users
representative of those likely to use the product. The aims
of these two types of validation differ, as the first focuses
primarily on the analytical characteristics of theHPT,while
the second assesses whether the HPT is fit for purpose in
the hands of the lay user. The urgent need for international
guidance on validation of HPTs is clear from the variation
in practice shown in Table 2 and Supplementary Table 1.
During laboratory testing, technicians should handle the
tests according to the instructions for use, for example, lie
on a flat surface and replace cap if this is detailed in the
instructions. If a different testing procedure is used, there
should be statistically robust studies showing equivalence
of methods.
Specimen requirements for validation studies
It is essential that HPT validation studies of both types are
performed using urine. Validation studies for methods
appropriate for use with blood or serum specimens must
also be performed in thesematrices. hCG standards used to
assess detection limits should be prepared in the relevant
matrices from pre-menopausal non-pregnant women.
Samples should have urinary hCG <1 U/L, measured using
a quantitative assay validated for use in urine samples.
Alternatively, pregnancy status could be determined using
serum hCG concentration taken on the same day as the
urine sample. Given that it is relatively easy to source
female urine, there should be no need to use male urine,
which may not completely reflect the matrix in which tests
are ordinarily performed. When preparing standards,
specific gravity should be recorded and highly dilute urine
should not be used.
Validation panels should include specimens from in-
dividual women, both pregnant and non-pregnant. This is
in accordancewith FDAguidance,which states that at least
100 “fresh” authentic human urine specimens should be
used in validation testing of HPTs [15].
The conditions of collection for urine and other spec-
imens for HPT validation studies should be agreed, as
current definitions of what constitutes a “fresh” urine
specimen are vague and inadequate. Whether specimens
should be collected at a specified time of day must also be
considered. The time delay between collection of urine
specimens and their use in validation studies is particu-
larly important for manufacturers as it is unlikely to be
feasible to test specimens immediately after collection.
Conditions of storage, including temperature and the
maximum time of storage from when specimens are
collected until they are used in validation studies, need to
be specified. This is because studies have shown that
storage conditions can affect the measured concentration
of hCG in urine samples [19, 25, 32–34]. For example, sig-
nificant loss of immunoreactivity has been reported for
samples stored at −20 °C, but not at +4 °C or −80 °C [35].
Inclusion of agents to retard bacterial growth is advisable
for refrigerated samples (e.g. sodium azide) because bac-
terial enzymes have been reported to cleave the peptide
chains of hCG. Manufacturers should therefore validate
their storage and collection conditions if using banked
samples, and clearly describe these in the relevant tech-
nical data sheets.
The same considerations apply to lay users who are
testing specimens provided by the manufacturer, particu-
larly if this is being performed at home (Table 4). This is
likely to be less relevant when lay users are testing their
own urine, assuming they will test at the time of urination.
However, lay users participating in validation studies
should be reminded of this requirement and also advised of
the ideal time of day at which to test their urine if specific
timing is recommended in the instructionswith the product
(e.g. sampling the first morning urine).
Recommendation: Pre-analytical requirements for
urine collection and storage prior to validation studies
should be clearly defined.
Assessing analytical accuracy, sensitivity and
reproducibility of HPTs
It is very important to differentiate analytical and clinical
accuracy and sensitivity of HPTs, an issue that the panel
considered problematic, particularly in advertising claims
made for some HPTs. These distinctions should be
explained and the terms clearly defined in kit inserts and/
or technical data sheets.
Analytical accuracy
Analytical accuracy must be assessed by the manufacturer,
and reflected in kit inserts and/or technical data sheets in
the claimed detection limit or analytical sensitivity of the
method. These aremost often 10 or 25 U/L of hCGbutmay be
as high as 50 U/L or as low as 2 U/L. Analytical accuracy is
assessed using urine specimens containing known amounts
of added purified intact hCG, which has been calibrated
against the International Standard for hCG. Manufacturers
shoulddocument the versionof International Standardused
for calibration. The concentration ranges of these specimens
should include specimens below and above the claimed
detection limit of the method – concentrations that should
give consistently negative (not pregnant) or positive (preg-
nant) results. Specimens of intermediate concentrations
near the “transition” or “50:50” concentration (at which on
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half the testing occasions, the HPTwill give a positive result
and on the other half will give a negative result) should also
be included (See further discussion below). Test perfor-
mance at these concentrations is most likely to be affected
by factors such as different lot number or operator, thus
providing additional valuable information. Some panel
members recommendedadetection limit of 25U/L, but there
was no consensus.
Recommendation: The minimum number of urine
specimens containing added hCG and the appropriate
concentration range for validation of analytical accuracy
should be defined.
Analytical sensitivity
As HPTs are threshold-based tests rather than quantitative
tests, standard definitions of Limit of Detection (LoD) and
Limit of Quantification (LoQ) have not historically been
applied. Rather, tests have been described in terms of
“sensitivity”, meaning analytical sensitivity. The definition
of analytical sensitivity varies and in some data sheets is
“the lowest concentration of hCG which it is possible to
detect” rather than, as is appropriate, the lowest concen-
tration which the HPT detects reliably and reproducibly.
The panel agreed that the analytical sensitivity of HPTs
should be defined as the lowest concentration of hCG that
can be reliably detected more than 99% of the time.
Although it would be preferable to use LoD, the term
“sensitivity” is now being used by consumers and health-
care professionals to understand the performance of tests;
thus, a new term in consumer labelling would be unhelp-
ful. Details of how analytical sensitivity was assessed
should be included in technical data sheets.
Recommendation: Analytical sensitivity should be
expressed as the lowest concentration that the HPT de-
tects ≥99% the time.
Analytical precision
The precision of HPTs, which reflects their repeatability
and reproducibility [14], should be assessed during vali-
dation. Repeatability is a measurement of precision in
which replicate measurements using the same procedure,
operators, system, operating conditions location (labora-
tory) are conducted on the same or similar specimens over
a short period of time. Reproducibility aims to identify the
parameters that contribute to variability of the assay by
combining factors known to influence assay precision,
such as operators, lots and batches, in a matrix to provide
sufficient data points for statistical analysis. As presented
in Table 2, considerable variation in how the precision of
HPTs is currently assessed was reported. The panel agreed
that in accordance with recommendations for other labo-
ratory tests, repeatability should be assessed by obtaining
20 measurements from the same specimen (ideally a
pooled urine standard) at different hCG concentrations
representative of the working range of the assay. By
including specimens of appropriately low concentration,
the limit of detection can be determined similarly. Testing
the same samples across five non-consecutive days by
three different operators and for three different lot numbers
provides additional evidence of precision and reproduc-
ibility. Guidance regarding experimental design for repro-
ducibility is available from CLSI Evaluating Quantitative
Measurement Precision-A3 [36].
Table : Assessment of performance of four FDA-cleared HPTs with claimed analytical sensitivities of  U/L when used by non-laboratory
personnel (lay users).











Total number of lay
users
 ( strip,  cassette,
 mid-stream)
 ( strip,  cassette,




Testing specimens Own urine Own urine Own urine Own urine
Number of pregnant
volunteers
   
Number of non-
pregnant volunteers
   
Method for assessing




Ease of use questionnaire. Ease of use and leaflet comprehen-
sion questionnaire, and Flesch–
Kincaid analysis of leaflet to show
reading age of Grade .
Ease of use questionnaire and
Flesch–Kincaid analysis of
leaflet to show reading age of
Grade .
FDA, US Food and Drug Administration; HPT, home pregnancy test.
Sturgeon et al.: Validation testing of home pregnancy tests 829
Recommendation: Analytical precision should be
assessed by: (1) repeating the test at least 20 times per
condition, across standards which include hCG concen-
trations near the detection limit of the method and the
“50:50” point; and (2) repeating the testing series on at
least three separate days spaced across a minimum five-
day time frame, and with a minimum of three different
operators and three different lot numbers.
Analytical robustness to potential interferences
HPT validation studies should include evaluation of the
effect of potential clinically relevant cross-reactants,
including luteinising hormone (LH) at concentrations
that may be present in urine (e.g. 500 U/L). The FDA
requests that manufacturers also test follicle stimulating
hormone (e.g. 1,000 U/L) and thyroid stimulating hor-
mone (e.g. 1 U/L) [10, 11]. Dietary supplements such as
biotin may suppress signal production [37] causing erro-
neous results. Vulnerability to such interference should
be assessed during validation. The urine matrix used in
spiking experiments should have an appropriate pH (5–7)
and specific gravity (1.010–1.030).
High urinary concentrations of hCG in late pregnancy,
and of hCGβcf at the end of the first trimester and through
later pregnancy may saturate antibody binding sites in the
HPT, producing a false negative test result (i.e. the “hook
effect”) [2, 21, 38–41]. Validation of HPTs should include
testing to demonstrate that the test still returns “Pregnant”
results at high concentrations of hCG (e.g. 500,000 U/L).
For hCGβcf, validation studies should demonstrate that
“hooking” that results in false negative results does not
occur in clinically possible scenarios. This has to be done in
a matrix with high concentrations of intact hCG to mimic
the actual clinical conditions under which this phenome-
non has been observed to occur (e.g. hCGβcf diluted to
achieve a final concentration of 1 μmol/L into late first
trimester pooled urine) [2, 20, 21, 41–44].
Results of such validation studies should be included
in technical data sheets, which should also clearly state
whether concentrations above which the method is
affected are likely to be encountered in clinical specimens.
hCGβcf is likely to be found at the highest concentration in
urine at 10–12 weeks of gestation [43].
Recommendation: Cross-reactions with LH, hCGβcf
and other potential clinically relevant interferences should
be assessed in HPT validation studies and results docu-
mented in technical data sheets.
Robustness to potential errors when using the HPT
Although challenging to address, assessing the vulnera-
bility of the HPT to small errors in specimen application
(e.g. holding a mid-stream test in the urine stream for too
long, or adding too many urine drops to a cassette test) or
errors in timing prior to reading the tests should be
included in validation studies. Mid-stream tests often
provide two options for sample application: in-stream and
dipping; equivalency of these methods should be demon-
strated. If the HPT is insufficiently robust, it may be
necessary to consider re-designing method.
Clinical requirements for validation of HPTs
Assessment of clinical accuracy should provide users with
information about how accurately the test will identify
pregnancy status at the time the sample is taken, and
should include robust data with a statistically appropriate
sample size and clear definition of how pregnancy status is
defined. Particular attention is required during validation
studies to address the following issues.
Validation of claims for “early pregnancy testing”
Manufacturers making claims relating to “early pregnancy
testing” (often described as “testing before the missed
period”) should be fully transparent regarding the pro-
portion of pregnancies detected when testing so early and
provide data supporting their claim. It is not clear whether
many of the tests available in Europe have validated their
early claim performance on clinical samples and if so, how
thiswas achieved or how the specimenswere collected. It is
likely that rather than conducting studies examining early
pregnancy detection rate, some may base the claim purely
on the analytical sensitivity of the test.
The language surrounding early testing claims ap-
pears to have arrived at a common terminology, “testing
before the missed period”, and as consumers are familiar
with seeing data presented using the missed period as
reference, moving to alternative, more precise termswould
be confusing. The timing of the missed period is notably
inaccurate, especially for women with irregular periods,
but unless the woman is monitoring ovulation using
home ovulation tests or undergoing in vitro fertilisation,
there is currently no better method for assessing when to
time a test. Claims on currently marketed HPTs tend to be
derived from calculating day of expected period as
15 days following ovulation, where ovulation day can be
determined by a variety of methods (pre-conception day
of LH surge [urine or serum], or use of urinary oestrone-
3-glucuronide:pregnanediol-3-glucuronide ratio or ul-
trasound observed ovulation). Although this may not
necessarily mirror the day a consumer would calculate, it
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does enable direct comparison between performance
characteristics of different tests.
Claims such as “Results over 99% accurate from the
day of your expected period” should be supported by
referenced clinical studies.
Recommendation: Data supporting claims for early
pregnancy testing should be provided and how studieswere
conducted described in full in the technical data sheet.
Potential disadvantages of highly sensitive HPTs
HPT methods should be designed so that analytical
sensitivity is not so high that it generates “apparently
false” positive results in women experiencing early preg-
nancy loss, which depending on the circumstances can be
very distressing. Approximately one in four pregnancies
end in early pregnancy loss, many of which will cause a
positive HPT result at the time of the firstmissed period [43,
45, 46]. In addition, hCG concentrations in non-pregnant
peri- and post-menopausal women can be slightly raised
relative to the pre-menopausal reference interval [47];
therefore, HPTs should be assessed for specificity when
used bywomen in this age group. This issue is increasingly
relevant as more women delay pregnancy until a later age
when irregular periods, often associated with the peri-
menopause, may be mistaken for pregnancy, prompting a
pregnancy test. It has been suggested that an upper refer-
ence limit of 14 U/L should be used when interpreting
serum hCG results in women >55 years of age [47]. Manu-
facturers should quantify this risk for each HPT and
consider including this information in the package insert if
the risk is relatively high.
Recommendation: Potential drawbacks of highly
sensitive HPTs should be assessed and relevant informa-
tion included in technical data sheets and package inserts.
Misleading claims of 100% accuracy
The panel was particularly concerned that claims of “100%
accuracy”made for some HPTs can be misleading to health
professionals and lay users as it is often not clear whether
“100%” relates to analytical or clinical accuracy. Lay users
in particular are likely to assume such claims mean that an
HPT is 100% clinically accurate for the detection of preg-
nancy. This is never the case due to potentially confounding
factors, including specimens that are too dilute or the pos-
sibility of early pregnancy loss, as well as the nature of all
immunoassays. Such claims could be exploited by manu-
facturers to imply that their test is clinically superior. In
agreementwith current FDAguidance, the panel agreed that
such claims should not be permitted in Europe.
Recommendation: Statements that HPTs are 100%
accurate should not be permitted in data sheets or other
promotional material.
Requirements for validation of HPTs by lay
users
HPTs are developed primarily for lay users who generally
will have little practical experience of laboratory testing. It
is important to ensure that HPTs include clear instructions
for use, that the tests can be readily performed outside a
laboratory environment, that they are robust and that
interpretation of the results is straightforward. Incorpo-
rating lay user testing during validation of HPTs is there-
fore essential to assess ease of use and confirm whether
intended users are readily able to follow the product in-
structions, as well as to ensure that test results are inter-
preted correctly. The lay user panel should include a
reasonable number of representative women from a range
of age groups and its composition should be described in
the technical data sheet. Panels would ideally include
women seeking to become pregnant and women who
suspect pregnancy (whether wanted or unwanted) because
their period is late. In practice, however, recruiting women
in the latter group is likely to be more difficult.
The results obtained by lay users testing their own
sample should be compared to their true clinical status, as
determined by an independent method. This is especially
important as lay users may be less able than laboratory
staff to read fainter lines at the test sensitivity. The study
should be sufficiently sized to enable clinical accuracy,
sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) to be calculated robustly,
as required by the IVDR.
Recommendation: Sensitivity, PPV and NPV should
be calculated.
Ease of use
Both practical and questionnaire assessments are likely to
be required. The latter could take the form of Likert-style
questionnaires, where participants provide responses to
questions such as “Howeasywas it to read the result?” on a
7-point scale ranging from 1 (e.g. “Extremely easy”) to 7
(e.g. “Extremely difficult”). Criteria for acceptability
should be established before questionnaires are issued.
Recommendation: A study where the HPT is used by
women representative of the lay user and the volunteer
results are compared to clinical pregnancy status should be
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conducted. The study should also consider ease of use,
with results presented in the technical data sheet.
Presentation of practical information on how to use
the HPT
Clear instructions about specimen collection
The clarity of instructions regarding how to collect urine
specimens and apply the specimen to the HPT should be
assessed as how the specimen is applied to the device may
influence the results. For example, some tests require
uniform flow of urine through the test strip. If this is per-
turbed because too much or too little urine is applied,
erroneous results may be obtained. Validation studies
should demonstrate the results from lay user testing match
those for similar urine specimens as tested by laboratory
professionals [12].
Clear instructions about timing
Clear instructions about timing, both from the time of
sample collection to the time of use of the HPT, and be-
tween application of urine to the device and the read time,
should be included in the information leaflet. Additionally,
the maximum time period for which the result remains
valid from the time of running the test should be noted.
This is because when lateral flow-based tests dry out, line
intensity canbe altered to no longer reflect the true result of
the test, so there is usually a maximum reading time.
Recommendation: Information providedwith theHPT
should include clear and detailed instructions about urine
collection and timing between steps in the testing process.
The clarity of these instructions should be assessed in
practice by an appropriately constituted panel of lay users
during validation of the HPT.
Presentation of information on interpretation of HPT
results
General format of information provided
Information should be clearly presented using wording
readily understood by the general public, including young
teenagers, and should avoid use of scientific terms wher-
ever possible. The font size on all package labelling and
information leaflets should be large enough to be readily
legible.
Shelf life
HPTs have a defined shelf life as determined by stability
studies, which should be conducted by the manufacturer
(usually 2–3 years). The “use by” date should be clearly
printed on the test carton.
Error results
As with any immunoassay, HPTs can occasionally fail to
function properly, whether due to over- or under-sampling,
or misuse by the lay user, or due to a faulty test (e.g.
damaged in shipping). Therefore, it is important that a lay
user is able to understandwhen a test result is an error, and
not misinterpret the result as “Not pregnant” (e.g. no lines
on the test) or “Pregnant” (e.g. just the test line visible). The
instructions for use should clearly provide information on
what error results present like.
Information about test interpretation
Information leaflets should include a statement that HPTs
are not 100% accurate for confirmation of pregnancy and
that negative tests should be repeated if there is a strong
suspicion of pregnancy. Clear images of the different re-
sults should be included to aid interpretation.
Inappropriately negative results may be obtained in
early pregnancy if hCG concentrations are not high enough
for detection or if urine is very dilute (earlymorning urine is
often requested to reduce this risk). Repeating the test
3–5 days later is generally desirable. Measurement of
serum hCG when requested by the woman’s healthcare
provider is another option that should provide a definitive
answer. This is essential if the woman is experiencing
abdominal pain or bleeding as these may indicate an
ectopic pregnancy, which can produce very low concen-
trations of hCG [41, 48, 49].
Recommendation: Information leaflets provided
with the HPT should include clear and detailed infor-
mation about the limitations of HPTs. The clarity of the
information provided should be assessed through ques-
tionnaires provided to lay users participating in the
analytical validation studies.
Conclusions
The authors trust that the recommendations proposed here
for validation of HPTs may constructively contribute to
improved standardisation of validation procedures for
HPTs in Europe. Defining best practice at all stages of
validation of these important tests should help to ensure
that tests marketed in Europe are fit for purpose and that
lay users can be confident of the high quality of the HPT
results they obtain.
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